Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (OnlineFirst PDF)
Right arrow All Versions of this Article:
1352458508089228v1
14/6/830    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Gneiss, C.
Right arrow Articles by Deisenhammer, F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gneiss, C.
Right arrow Articles by Deisenhammer, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
First published on June 5, 2008, doi:10.1177/1352458508089228

Multiple Sclerosis 2008;14:830.

A more recent version of this article appeared on July 1, 2008

Article

Comparative study of four different assays for the detection of binding antibodies against interferon-{beta}

C. Gneiss1, M. Brugger1, A. Millonig1, A. Fogdell-Hahn2, D. Rudzki1, J. Hillert2, T. Berger1, M. Reindl1, and F. Deisenhammer1*

1 Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse, Innsbruck, Austria
2 Division of Neurology, Karolinska Institutet, Clinical Neuroscience, Karolinska University Hospital, Huddinge, Stockholm, Sweden

* To whom correspondence should be addressed.


  Abstract

Background

Binding antibodies (BAB) against interferon-{beta} (IFN{beta}) are often determined as screening assays before performing an expensive and elaborate neutralizing antibody (NAB) test.

Methods

In this study, we compared four BAB tests, a western blot (WB), a direct binding enzyme-linked immunosorbent assay (ELISA) (dELISA), a capture ELISA (cELISA), and a commercial enzyme immuno-assay (EIA) in 325 multiple sclerosis patients with and without neutralizing antibodies to evaluate the sensitivity and specificity to detect NAB by receiver operating characteristics analysis.

Results

The area under the curve (AUC) values were 0.907 for the dELISA, 0.925 for the cELISA, and 0.776 for the EIA (P < 0.0001 for all). At a sensitivity of 95%, the specificity was approximately 30% in the dELISA, 55% in the cELISA, and 13% in the EIA. The WB as a qualitative BAB detection method had a given sensitivity of 97% and a specificity of 55%. There was a strong and significant correlation between high NAB titers (>500 neutralizing units [NU]) and titers obtained by all quantitative BAB assays. However, low to medium NAB titers (20–500 NU) did not significantly correlate with BAB titers.

Conclusion

We conclude that the cELISA seems to be most suitable for NAB screening, but BAB titers cannot reliably predict NAB titers.

Key Words: antibodies, binding, enzyme-linked immunosorbent assay, interferon-{beta}, multiple sclerosis, neutralizing, western blot


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?